Research programme: microbiome therapeutics - Seres Therapeutics

Drug Profile

Research programme: microbiome therapeutics - Seres Therapeutics

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator Seres Therapeutics
  • Developer Massachusetts General Hospital; Seres Therapeutics; University of Pennsylvania
  • Class Bacteria
  • Mechanism of Action Bacteria replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Inflammatory bowel diseases; Metabolic disorders; Metabolic syndrome

Most Recent Events

  • 16 Mar 2017 Seres Therapeutics has patent protection for microbiome therapeutics in USA
  • 10 Nov 2016 Seres Therapeutics has patent protection for microbiome therapeutics in USA
  • 12 Jul 2016 Seres Therapeutics and Emulate collaborate for the development of microbiome therapeutics in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top